Verona Pharma PLC American Depositary Share $VRNA Stake Raised by GAMMA Investing LLC

GAMMA Investing LLC boosted its holdings in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 5.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,940 shares of the company’s stock after acquiring an additional 103 shares during the quarter. GAMMA Investing LLC’s holdings in Verona Pharma PLC American Depositary Share were worth $183,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Northern Trust Corp acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the fourth quarter worth approximately $362,000. Two Sigma Advisers LP acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the 4th quarter valued at $882,000. NBC Securities Inc. acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at $34,000. RFG Advisory LLC purchased a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at $1,475,000. Finally, Hamilton Lane Advisors LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share in the first quarter worth $1,654,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of VRNA opened at $106.69 on Monday. The company has a market capitalization of $9.20 billion, a PE ratio of -107.77 and a beta of 0.14. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. Verona Pharma PLC American Depositary Share has a one year low of $27.54 and a one year high of $106.75. The company’s fifty day moving average price is $105.74 and its 200 day moving average price is $86.52.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.14. The company had revenue of $103.14 million for the quarter, compared to the consensus estimate of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. As a group, analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRNA has been the subject of a number of research reports. Piper Sandler cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Jefferies Financial Group reiterated a “hold” rating and set a $107.00 price target (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, July 9th. BTIG Research cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. HC Wainwright reaffirmed a “neutral” rating and set a $107.00 price objective (up previously from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, July 14th. Finally, Truist Financial downgraded shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 9th. Two investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $109.00.

Insider Transactions at Verona Pharma PLC American Depositary Share

In other news, Director Martin Edwards sold 10,808 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $142,017.12. Following the completion of the sale, the director directly owned 157,992 shares of the company’s stock, valued at approximately $2,076,014.88. This represents a 6.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David R. Ebsworth sold 1,904 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $25,018.56. Following the completion of the sale, the director owned 880,499 shares in the company, valued at approximately $11,569,756.86. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 540,584 shares of company stock worth $7,103,274. Insiders own 4.80% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.